The Motley Fool Previous Page


2 Risks That Could Crush MannKind in 2013

http://www.fool.com/investing/general/2013/01/03/2-risks-that-could-crush-mannkind-in.aspx

Keith Speights
January 3, 2013

MannKind (NASDAQ: MNKD) -- one of the most contentious biotech stocks of 2012 -- has kept investors on the edge of their seats. As the company works toward approval from the Food and Drug Administration, investors continue to debate the ultimate commercial potential of MannKind's ultra-rapid inhalable insulin product, Afrezza. Can this company revolutionize the way diabetes is treated and become a blockbuster, or will Afrezza be a massive flop? 

In a brand new